Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Usefulness of liquid biopsy biomarkers from aqueous humor in predicting Anti-VEGF response in diabetic macular edema: results of a pilot study

  • Udaondo, Patricia
  • Hernández Pascual, Cristina
  • Brianso Llort, Laura
  • García-Delpech, Salvador
  • Simó Servat, Olga
  • Simó Canonge, Rafael
Diabetic macular edema; Anti-VEGF agents; Aqueous humor, Edema macular diabético; Agentes anti-VEGF; Humor acuoso, Edema macular diabètic; Agents anti-VEGF; Humor aquós, The objective was to investigate the usefulness of the “liquid biopsy” of aqueous humor (AH) to predict the clinical response after intravitreal injections (IVT) of anti-VEGF agents for treating diabetic macular edema (DME). For this purpose, AH samples obtained during the first anti-VEGF IVT from 31 type two diabetic patients were analyzed. Patients were classified into three groups according to their anti-VEGF response: rapid responders (n = 11), slow responders (n = 11), and non-responders (n = 9). In addition, patients (n = 7) who showed good response to corticosteroids but a delayed or no response to anti-VEGF therapy were analyzed. Levels of 17 different cytokines, chemokines, and growth factors in AH were measured using a multiplex immunoassay. We found higher concentrations of VEGF in rapid responders to anti-VEGF therapy compared to non-responders. In addition, slow responders to anti-VEGF treatment showed higher levels of inflammatory markers than rapid responders, but did not reach statistical significance. Finally, those patients who responded to corticosteroids but not to anti-VEGF therapy showed significantly lower levels of VEGF than patients with rapid response (p = 0.01). In conclusion, “liquid biopsy” of AH could be useful to determine whether the predominant pathogenic event is primarily angiogenic or inflammatory in nature. This approach would allow physicians to select a more rational and cost-effective treatment. Further studies to validate these preliminary results are warranted., This study was supported by grants from F. Hoffmann-La Roche Ltd. and Instituto de Salud Carlos III (PI16/00541). Laura Brianso is a recipient of a Predoctoral Research Grant from Instituto de Salud Carlos III (FI17/00213).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes

  • Bogdanov Baruj, Patricia
  • Ramos Abellan, Hugo
  • Huerta Alonso, Jordi
  • Simó Servat, Olga
  • Hernández Pascual, Cristina
  • Simó Canonge, Rafael
Diabetic retinopathy; Retina; Semaglutide, Retinopatia diabètica; Retina; Semaglutida, Retinopatía diabética; Retina; Semaglutida, Background: An unexpected increase in the rate of severe diabetic retinopathy was observed in the Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN)-6 clinical trial. Although this effect was attributed to a rapid decrease in blood glucose levels, a direct deleterious effect of semaglutide on the retina could not be ruled out. In order to shed light on this issue, we have performed a study aimed at testing the direct effect of semaglutide administered by eye drops on retinal neuroinflammation and microvascular abnormalities using the db/db mouse model. Methods: Eye drops containing semaglutide (0.33 mg/mL; 5 μL once/daily) or vehicle (PBS; 5 μL once daily) were administered for 15 days. Results: We found that semaglutide significantly reduced glial activation, as well as the retinal expression of Nuclear factor kB (NF-κB), proinflammatory cytokines (IL-1β, IL-6, IL-18) and Intercellular Adhesion Molecule (ICAM)-1. In addition, semaglutide prevented the apoptosis of cells from the retinal ganglion layer and activated the protein kinase B (AKT) pathway. Finally, a dramatic decrease in vascular leakage was observed in db/db mice treated with semaglutide. All these findings were observed without any change in blood glucose levels and, therefore, can be directly attributed to semaglutide. Conclusions: These experimental findings point to a beneficial rather than a deleterious effect of semaglutide on the retina of subjects with diabetes., This research was funded by grants from the Ministerio de Economía y Competitividad (PI16/00541, PI19/01215 and SAF2016-77784) and the Fundació La Marató TV3 (201629-10). The study funder was not involved in the design of the study.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

SOCS1-derived peptide administered by eye drops prevents retinal neuroinflammation and vascular leakage in experimental diabetes

  • Hernández, Cristina|||0000-0002-3109-1721
  • Bogdanov, Patricia|||0000-0003-0669-4958
  • Gómez-Guerrero, Carmen|||0000-0001-9001-5414
  • Sampedro, J.
  • Solà-Adell, C.
  • Espejo, Carmen|||0000-0001-9949-5901
  • Garcia-Ramírez, Marta
  • Prieto, I.
  • Egido, Jesús
  • Simó, R.
Current treatments for diabetic retinopathy (DR) target late stages when vision has already been significantly affected. Accumulating evidence suggests that neuroinflammation plays a major role in the pathogenesis of DR, resulting in the disruption of the blood-retinal barrier. Suppressors of cytokine signaling (SOCS) are cytokine-inducible proteins that function as a negative feedback loop regulating cytokine responses. On this basis, the aim of the present study was to evaluate the effect of a SOCS1-derived peptide administered by eye drops (2 weeks) on retinal neuroinflammation and early microvascular abnormalities in a db/db mouse model. In brief, we found that SOCS1-derived peptide significantly reduced glial activation and neural apoptosis induced by diabetes, as well as retinal levels of proinflammatory cytokines. Moreover, a significant improvement of electroretinogram parameters was observed, thus revealing a clear impact of the histological findings on global retinal function. Finally, SOCS1-derived peptide prevented the disruption of the blood-retinal barrier. Overall, our results suggest that topical administration of SOCS1-derived peptide is effective in preventing retinal neuroinflammation and early microvascular impairment. These findings could open up a new strategy for the treatment of early stages of DR.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Beneficial Effects of Glucagon-Like Peptide-1 (GLP-1) in Diabetes-Induced Retinal Abnormalities, Involvement of Oxidative Stress

  • Ramos, Hugo|||0000-0001-6443-7576
  • Bogdanov, Patricia|||0000-0003-0669-4958
  • Sampedro, Joel|||0000-0002-8463-7740
  • Huerta, Jordi|||0000-0002-9908-8051
  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Hernández, Cristina|||0000-0002-3109-1721
Background: Hyperglycemia-induced oxidative stress plays a key role in diabetic complications, including diabetic retinopathy. The main goal of this study was to assess whether the topical administration (eye drops) of glucagon-like peptide-1 (GLP-1) has any effect on oxidative stress in the retina. Methods: db/db mice were treated with eye drops of GLP-1 or vehicle for three weeks, with db/+ mice being used as control. Studies included the assessment by western blot of the antioxidant defense markers CuZnSOD, MnSOD, glutathione peroxidase and reductase; immunofluorescence measurements of DNA/RNA damage, nitro tyrosine and Ki67 and Babam2 proteins. Results: GLP-1 eye drops protected from oxidative stress by increasing the protein levels of glutathione reductase, glutathione peroxidase and CuZnSOD and MnSOD in diabetic retinas. This was associated with a significant reduction of DNA/RNA damage and the activation of proteins involved in DNA repair in the retina (Babam2) and Ki67 (a biomarker of cell proliferation). Conclusions: GLP-1 modulates the antioxidant defense system in the diabetic retina and has a neuroprotective action favoring DNA repair and neuron cells proliferation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effects of the topical administration of semaglutide on retinal neuroinflammation and vascular leakage in experimental diabetes

  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Bogdanov, Patricia|||0000-0003-0669-4958
  • Ramos, Hugo|||0000-0001-6443-7576
  • Huerta, Jordi|||0000-0002-9908-8051
  • Simó-Servat, Olga|||0000-0003-3483-652X
  • Hernández, Cristina|||0000-0002-3109-1721
Background: An unexpected increase in the rate of severe diabetic retinopathy was observed in the Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN)-6 clinical trial. Although this effect was attributed to a rapid decrease in blood glucose levels, a direct deleterious effect of semaglutide on the retina could not be ruled out. In order to shed light on this issue, we have performed a study aimed at testing the direct effect of semaglutide administered by eye drops on retinal neuroinflammation and microvascular abnormalities using the db/db mouse model. Methods: Eye drops containing semaglutide (0.33 mg/mL; 5 µL once/daily) or vehicle (PBS; 5 µL once daily) were administered for 15 days. Results: We found that semaglutide significantly reduced glial activation, as well as the retinal expression of Nuclear factor kB (NF-κB), proinflammatory cytokines (IL-1β, IL-6, IL-18) and Intercellular Adhesion Molecule (ICAM)-1. In addition, semaglutide prevented the apoptosis of cells from the retinal ganglion layer and activated the protein kinase B (AKT) pathway. Finally, a dramatic decrease in vascular leakage was observed in db/db mice treated with semaglu-tide. All these findings were observed without any change in blood glucose levels and, therefore, can be directly attributed to semaglutide. Conclusions: These experimental findings point to a beneficial rather than a deleterious effect of semaglutide on the retina of subjects with diabetes. 0926.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Usefulness of liquid biopsy biomarkers from aqueous humor in predicting Anti-VEGF response in diabetic macular edema: results of a pilot study

  • Udaondo, Patricia
  • Hernández Pascual, Cristina
  • Brianso Llort, Laura
  • García-Delpech, Salvador
  • Simó Servat, Olga
  • Simó Canonge, Rafael
Diabetic macular edema; Anti-VEGF agents; Aqueous humor, Edema macular diabético; Agentes anti-VEGF; Humor acuoso, Edema macular diabètic; Agents anti-VEGF; Humor aquós, The objective was to investigate the usefulness of the “liquid biopsy” of aqueous humor (AH) to predict the clinical response after intravitreal injections (IVT) of anti-VEGF agents for treating diabetic macular edema (DME). For this purpose, AH samples obtained during the first anti-VEGF IVT from 31 type two diabetic patients were analyzed. Patients were classified into three groups according to their anti-VEGF response: rapid responders (n = 11), slow responders (n = 11), and non-responders (n = 9). In addition, patients (n = 7) who showed good response to corticosteroids but a delayed or no response to anti-VEGF therapy were analyzed. Levels of 17 different cytokines, chemokines, and growth factors in AH were measured using a multiplex immunoassay. We found higher concentrations of VEGF in rapid responders to anti-VEGF therapy compared to non-responders. In addition, slow responders to anti-VEGF treatment showed higher levels of inflammatory markers than rapid responders, but did not reach statistical significance. Finally, those patients who responded to corticosteroids but not to anti-VEGF therapy showed significantly lower levels of VEGF than patients with rapid response (p = 0.01). In conclusion, “liquid biopsy” of AH could be useful to determine whether the predominant pathogenic event is primarily angiogenic or inflammatory in nature. This approach would allow physicians to select a more rational and cost-effective treatment. Further studies to validate these preliminary results are warranted., This study was supported by grants from F. Hoffmann-La Roche Ltd. and Instituto de Salud Carlos III (PI16/00541). Laura Brianso is a recipient of a Predoctoral Research Grant from Instituto de Salud Carlos III (FI17/00213).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes

  • Bogdanov Baruj, Patricia
  • Ramos Abellán, Hugo
  • Huerta Alonso, Jordi
  • Simó Servat, Olga
  • Hernández Pascual, Cristina
  • Simó Canonge, Rafael
Diabetic retinopathy; Retina; Semaglutide, Retinopatia diabètica; Retina; Semaglutida, Retinopatía diabética; Retina; Semaglutida, Background: An unexpected increase in the rate of severe diabetic retinopathy was observed in the Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN)-6 clinical trial. Although this effect was attributed to a rapid decrease in blood glucose levels, a direct deleterious effect of semaglutide on the retina could not be ruled out. In order to shed light on this issue, we have performed a study aimed at testing the direct effect of semaglutide administered by eye drops on retinal neuroinflammation and microvascular abnormalities using the db/db mouse model. Methods: Eye drops containing semaglutide (0.33 mg/mL; 5 μL once/daily) or vehicle (PBS; 5 μL once daily) were administered for 15 days. Results: We found that semaglutide significantly reduced glial activation, as well as the retinal expression of Nuclear factor kB (NF-κB), proinflammatory cytokines (IL-1β, IL-6, IL-18) and Intercellular Adhesion Molecule (ICAM)-1. In addition, semaglutide prevented the apoptosis of cells from the retinal ganglion layer and activated the protein kinase B (AKT) pathway. Finally, a dramatic decrease in vascular leakage was observed in db/db mice treated with semaglutide. All these findings were observed without any change in blood glucose levels and, therefore, can be directly attributed to semaglutide. Conclusions: These experimental findings point to a beneficial rather than a deleterious effect of semaglutide on the retina of subjects with diabetes., This research was funded by grants from the Ministerio de Economía y Competitividad (PI16/00541, PI19/01215 and SAF2016-77784) and the Fundació La Marató TV3 (201629-10). The study funder was not involved in the design of the study.